Innocoll Holdings PLC (INNL) & Its Competitors Critical Contrast
Innocoll Holdings PLC (NASDAQ: INNL) is one of 113 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Innocoll Holdings PLC to related businesses based on the strength of its earnings, profitability, valuation, analyst recommendations, dividends, institutional ownership and risk.
Earnings & Valuation
This table compares Innocoll Holdings PLC and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Innocoll Holdings PLC||N/A||N/A||-1.41|
|Innocoll Holdings PLC Competitors||$7.79 billion||$2.46 billion||0.24|
Innocoll Holdings PLC’s rivals have higher revenue and earnings than Innocoll Holdings PLC. Innocoll Holdings PLC is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Innocoll Holdings PLC and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innocoll Holdings PLC||-1,051.20%||N/A||-138.53%|
|Innocoll Holdings PLC Competitors||-3,193.15%||-54.97%||-8.89%|
Institutional and Insider Ownership
34.2% of Innocoll Holdings PLC shares are owned by institutional investors. Comparatively, 43.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 12.0% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Innocoll Holdings PLC has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, Innocoll Holdings PLC’s rivals have a beta of 0.87, suggesting that their average stock price is 13% less volatile than the S&P 500.
This is a summary of current ratings and target prices for Innocoll Holdings PLC and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innocoll Holdings PLC||0||3||1||0||2.25|
|Innocoll Holdings PLC Competitors||789||3404||5856||137||2.52|
Innocoll Holdings PLC currently has a consensus target price of $4.50, suggesting a potential upside of 91.49%. As a group, “Pharmaceuticals” companies have a potential upside of 21.80%. Given Innocoll Holdings PLC’s higher possible upside, equities analysts plainly believe Innocoll Holdings PLC is more favorable than its rivals.
Innocoll Holdings PLC rivals beat Innocoll Holdings PLC on 8 of the 11 factors compared.
About Innocoll Holdings PLC
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with MarketBeat.com's FREE daily email newsletter.